

SAFETY DATA SHEET

SECTION 1: IDENTIFICATION

Sodium Chloride Injection, USP Product Name: Manufacturer Name: Fresenius Kabi USA, LLC

Address: Three Corporate Drive Lake Zurich, Illinois 60047

General Phone Number: (847) 550-2300 Customer Service Phone (888) 386-1300

Number:

Health Issues Information: (800) 551-7176 SDS Creation Date: January 08, 2009 June 10, 2015 SDS Revision Date:

(M)SDS Format:

SECTION 2: HAZARD(S) IDENTIFICATION

GHS Pictograms:

Signal Word: WARNING.

GHS Class: Eye Irritation. Category 2. Hazard Statements: Causes serious eye irritation.

Precautionary Statements:

Wash hands thoroughly after handling.
Wear protective gloves/protective clothing/eye protection/face protection.
IF IN EYES: Rinse cautiously with water for several minutes. Remove contact lenses, if present and easy

to do. Continue rinsing.

If eye irritation persists: Get medical advice/attention.

This product is intended for therapeutic use only when prescribed by a physician. Potential adverse reactions from prescribed doses and overdoses are described in the package insert. Emergency Overview:

Route of Exposure: Inhalation Ingestion Eye contact Skin Absorption. Injection.

Potential Health Effects:

Contact with eyes may cause irritation.

Skin: May cause skin irritation.

Inhalation: May cause irritation of respiratory tract.

Ingestion: May cause irritation.

Adverse reactions from prescribed doses include: febrile response, local tenderness, abscess, tissue necrosis, infection at injection site, venous thrombosis, phlebitis extending from the site of injection, and extravasation. Occupational exposure has not been fully investigated. Signs/Symptoms:

Aggravation of Pre-Existing Conditions:

Individuals with hypernatremia or fluid retention.

SECTION 3: COMPOSITION/INFORMATION ON INGREDIENTS

Chemical Name	CAS#	Ingredient Percent	EC Num.
Hydrochloric acid	7647-01-0	0.9 %	
Sodium hydroxide	1310-73-2	quantity sufficient	
Sodium Chloride	7647-14-5	0.9 %	
Water for Injection	7732-18-5	quantity sufficient	

SECTION 4: FIRST AID MEASURES

Immediately flush eyes with plenty of water for at least 15 to 20 minutes. Ensure adequate flushing of the eyes by separating the eyelids with fingers. Get immediate medical attention. Eye Contact:

Immediately wash skin with plenty of soap and water for 15 to 20 minutes, while removing contaminated clothing and shoes. Skin Contact:

Get medical attention if irritation develops or persists.

If inhaled, remove to fresh air. If not breathing, give artificial respiration or give oxygen by trained personnel. Seek immediate medical attention. Inhalation:

If conscious, flush mouth out with water immediately. Call a physician or poison control center immediately. Do not induce vomiting unless directed to do so by medical personnel. Never give Ingestion:

anything by mouth to an unconscious person.

Other First Aid: For Adverse Event Information, please call (800) 551-7176.

SECTION 5: FIRE FIGHTING MEASURES

Flash Point: Not established. Flash Point Method: Not established. Auto Ignition Temperature: Not established Lower Flammable/Explosive Limit: Not established. Upper Flammable/Explosive Limit: Not established

Evacuate area of unprotected personnel. Use cold water spray to cool fire exposed containers to minimize risk of rupture. Do not enter confined fire space without full protective gear. If possible, Fire Fighting Instructions:

contain fire run-off water.

Extinguishing Media: Use alcohol resistant foam, carbon dioxide, dry chemical, or water fog or spray when fighting fires

involving this material.

Use extinguishing measures that are appropriate to local circumstances and the surrounding environment.

Protective Equipment: As in any fire, wear Self-Contained Breathing Apparatus (SCBA), MSHA/NIOSH (approved or equivalent)

and full protective gear.

Hazardous Combustion

Byproducts:

Thermal decomposition products may include smoke and toxic fumes. Oxides of carbon, oxides of nitrogen and other organic substances may be formed. Other undetermined low molecular weight hydrocarbon compounds may be released in small quantities depending upon specific conditions of

combustion.

SECTION 6: ACCIDENTAL RELEASE MEASURES

Personnel Precautions: Evacuate area and keep unnecessary and unprotected personnel from entering the spill area

Avoid personal contact and breathing vapors or mists. Use proper personal protective equipment as

Environmental Precautions: Avoid runoff into storm sewers, ditches, and waterways.

Methods for containment: Contain spills with an inert absorbent material such as soil, sand or oil dry.

Absorb spill with inert material (e,g., dry sand or earth), then place in a chemical waste container. After removal, flush spill area with soap and water to remove trace residue. Methods for cleanup:

SECTION 7: HANDLING and STORAGE

When handling pharmaceutical products, avoid all contact and inhalation of vapor, mists and/or fumes. Use with adequate ventilation. Use only in accordance with directions. Handling:

Store at controlled room temperature 20 to 25°C (68 to 77°F). [See USP Controlled Room Storage:

Temperature]. Do not freeze

Facilities storing or utilizing this material should be equipped with an evewash facility and a safety Work Practices:

Hygiene Practices: Wash thoroughly after handling. Avoid contact with eyes and skin. Avoid inhaling vapor or mist.

SECTION 8: EXPOSURE CONTROLS, PERSONAL PROTECTION

Engineering Controls: General ventilation is sufficient if this product is being used in a controlled medical setting (clinic,

hospital, medical office) for its sole intended parenteral (injection) purpose. Otherwise, use appropriate engineering control such as process enclosures, local exhaust ventilation, or other engineering controls including use of a biosafety cabinet / fume hood to control airborne levels below recommended

exposure limits.

Eye/Face Protection: Chemical splash goggles. Wear a face shield also when splash hazard exist.

Skin Protection Description: Protective laboratory coat, apron, or disposable garment recommended

Hand Protection Description: Wear appropriate protective gloves. Consult glove manufacturer's data for permeability data. Nitrile rubber or natural rubber gloves are recommended.

Respiratory Protection: No personal respiratory protective equipment is normally required when this product is being

used/administered by a licensed healthcare practitioner (i.e. an end-user such as a clinician / doctor / nurse) for its sole intended parenteral (injection) purpose in a controlled medical setting. The need for respiratory protection will vary according to the airborne concentrations and environmental conditions. A NIOSH approved air-purifying respirator with an organic vapor cartridge or canister may be permissible under certain circumstances. Consult the NIOSH web site

(http://www.cdc.gov/niosh/npptl/topics/respirators/) for a list of respirator types and approved suppliers.

Other Protective: Consult with local procedures for selection, training, inspection and maintenance of the personal

protective equipment.

Hydrochloric acid:

Solubility:

Guideline ACGIH: TLV-STEL: 2 ppm(ceiling) Guideline OSHA: OSHA PEL-STEL 5 ppm Ceiling/Peak

SECTION 9: PHYSICAL and CHEMICAL PROPERTIES

Liquid solution. Physical State:

Colorless. Color

Odor: Odorless.

Boiling Point: Not established.

Melting Point: Not established.

Not established. Vapor Density:

Not established. Vapor Pressure:

Percent Volatile: Not established.

pH: 4.5 - 7.0

Molecular Formula: Mixture

Molecular Weight: 58.44

Flash Point: Not established.

Not established. Flash Point Method:

Auto Ignition Temperature: Not established.

SECTION 10: STABILITY and REACTIVITY

Chemical Stability: Stable under normal temperatures and pressures.

Soluble, in water,

Hazardous Polymerization: Not reported.

Conditions to Avoid: Excessive heat may cause decomposition.

SECTION 11: TOXICOLOGICAL INFORMATION

Acute Toxicity: Eye, skin, and respiratory irritation may occur.

Acute Effects: Eye, skin, and respiratory irritation may occur.

Chronic Effects: None known.

Hydrochloric acid:

Eve: Eve - Rabbit Total particulate/dust (T): 5 mg/30S (RTECS)

Skin: Administration onto the skin - Human Standard Draize test.: 4 %/24H (RTECS)

Inhalation: Inhalation - Rat LC50: 3124 ppm/1H [Sense Organs and Special Senses (Olfaction) - effect, not

Inhalation - Rat LC50: 3124 ppm/1H [Sense Organs and Special Senses (Olfaction) - effect, not Otherwise specified Sense Organs and Special Senses (Eye) - Iritis]
Inhalation - Mouse LC50: 1108 ppm/1H [Sense Organs and Special Senses (Eye) - effect, not Otherwise specified Lungs, Thorax, or Respiration - Respiratory stimulation Skin and Appendages - Dermatitis, other (After systemic exposure)]
Inhalation - Rat LC50: 45000 mg/m3/5M [Lungs, Thorax, or Respiration - Acute pulmonary edema]
Inhalation - Rat LC50: 8300 mg/m3/30M [Lungs, Thorax, or Respiration - Acute pulmonary edema]
Inhalation - Mouse LC50: 8300 mg/m3/30M [Lungs, Thorax, or Respiration - Acute pulmonary edema]
Inhalation - LC50: 0.1 gm/m3 [Details of toxic effects not reported other than lethal dose value]
Inhalation - Rat LC50: 60938 mg/m3/5M [Lungs, Thorax, or Respiration - Acute pulmonary edema]
Inhalation - Mouse LC50: 7004 mg/m3/30M [Lungs, Thorax, or Respiration - Acute pulmonary edema]
Inhalation - Rat LC50: 3940 mg/m3/30M [Lungs, Thorax, or Respiration - Acute pulmonary edema]
Inhalation - Rat LC50: 3700 ppm/30M [Details of toxic effects not reported other than lethal dose value]

Inhalation - Mouse LC50: 2644 ppm/30M [Details of toxic effects not reported other than lethal dose

value] (RTECS)

Oral - Rabbit LD50: 900 mg/kg [Details of toxic effects not reported other than lethal dose value]

(RTECS)

Sodium hydroxide:

Inaestion:

Eye - Rabbit Standard Draize test.: 400 ug Eye:

Eye - Rabbit Standard Draize test.: 50 ug/24H (RTECS)

Skin: Administration onto the skin - Rabbit Standard Draize test.: 500 mg/24H

Ingestion: Oral - Rabbit LDLo: 500 mg/kg [Details of toxic effects not reported other than lethal dose value]

Sodium Chloride:

RTECS Number: VZ4725000

Eye - Rabbit Standard Draize test.: 10 mg [Moderate]

Administration onto the skin - Rabbit LD50: >10 gm/kg [Details of toxic effects not reported other than Skin:

lethal dose value]

Administration onto the skin - Rabbit Standard Draize test.: 50 mg/24H [mild] Administration onto the skin - Rabbit Standard Draize test.: 500 mg/24H [mild]

Inhalation: $Inhalation - Rat\ LC50: > 42\ gm/m3/1H\ [Details\ of\ toxic\ effects\ not\ reported\ other\ than\ lethal\ dose$

Ingestion: Oral - Mouse LD50: 4 gm/kg [Details of toxic effects not reported other than lethal dose value]

Oral - Rat LD50: 3000 mg/kg [Details of toxic effects not reported other than lethal dose value]

Other Toxicological Information: Intravenous. - Mouse LD50: 645 mg/kg [Details of toxic effects not reported other than lethal dose

Intravenous. - Rabbit LDLo: 1100 mg/kg [Behavioral - convulsions or effect on seizure threshold

Behavioral - muscle contraction or spasticity Cardiac - other changes]
Intravenous. - Guinea pig LDLo: 300 mg/kg [Details of toxic effects not reported other than lethal dose

Intravenous. - Mouse TDLo: 2.1 mg/kg [Vascular - other changes Blood - hemorrhage Skin and

Appendages - dermatitis, irritative (after systemic exposure)]
Intravenous. - Rabbit LDLo: 1.5 mg/kg [Details of toxic effects not reported other than lethal dose value1

Value]
Intravenous. - Rabbit TDLo: 0.04 mg/kg [Vascular - other changes Blood - hemorrhage Skin and Appendages - dermatitis, irritative (after systemic exposure)]
Subcutaneous - Rat LDLo: 3500 mg/kg [Behavioral - irritability]
Subcutaneous - Mouse LD50: 3 gm/kg [Details of toxic effects not reported other than lethal dose

Subcutaneous - Guinea pig LDLo: 2160 mg/kg [Details of toxic effects not reported other than lethal

Subcutaneous - Rabbit TDLo: 0.04 mg/kg [Vascular - other changes Skin and Appendages - dermatitis,

Subcutaneous - Rabbit 10Lo: 0.04 mg/kg [Vascular - other changes Skin and Appendages - dermat irritative (after systemic exposure)]
Subcutaneous - Mouse TDLo: 1900 mg/kg [Reproductive - Effects on Embryo or Fetus - fetal death]
Subcutaneous - Mouse TDLo: 1900 mg/kg [Reproductive - Specific Developmental Abnormalities - musculoskeletal system]

Subcutaneous - Mouse TDLo: 2500 mg/kg [Reproductive - Effects on Embryo or Fetus - fetotoxicity (except death, e.g., stunted fetus)]

Subcutaneous - Mouse TDLo: 13440 mg/kg [Reproductive - Fertility - abortion] Intraperitoneal. - Mouse LD50: 2602 mg/kg [Details of toxic effects not reported other than lethal dose

value1 Intraperitoneal. - Rat LD50: 2600 mg/kg [Details of toxic effects not reported other than lethal dose

value1 Intraperitoneal. - Rat LDLo: 3.72 gm/kg [Behavioral - tremor Behavioral - convulsions or effect on

seizure threshold]

Intraperitoneal. - Rat TDLo: 1710 mg/kg [Reproductive - Effects on Embryo or Fetus - fetotoxicity (except death, e.g., stunted fetus) Reproductive - Effects on Embryo or Fetus - fetal death

Reproductive - Specific Developmental Abnormalities - musculoskeletal system]
Intraperitoneal. - Rat TDLo: 10 gm/kg [Reproductive - Effects on Newborn - behavioral]
Intraperitoneal. - Rat Cytogenetic analysis: 2338 mg/kg

SECTION 12: ECOLOGICAL INFORMATION

Ecotoxicity: No ecotoxicity data was found for the product

Environmental Stability: No environmental information found for this product.

SECTION 13: DISPOSAL CONSIDERATIONS

Waste Disposal: Dispose of in accordance with Local, State, Federal and Provincial regulations.

SECTION 14: TRANSPORT INFORMATION

DOT Shipping Name: Not Regulated. DOT UN Number: Not Regulated

IATA Shipping Name: Non regulated. TATA UN Number: Non regulated.

IMDG UN NUmber: Non regulated. IMDG Shipping Name: Non regulated.

SECTION 15: REGULATORY INFORMATION

Hydrochloric acid:

Listed TSCA Inventory Status:

SARA: EPCRA - 40 CFR Part 372 - (SARA Title III) Section 313 Listed Chemical.

Section 302 EHS: EPCRA (SARA Title III) Section 302 (40 CFR Part 355) Extremely Hazardous Substances (EHS)

Threshold Planning Quantity (TPQ) in pounds.: 500 Lbs.

Section 304 RQ: EPCRA (SARA Title III) Section 304 Extremely Hazardous Substances (EHS) Reportable Quantities (RQ)

in pounds.: 5,000 Lbs.

Canada DSL: Listed

Canada IDL: Identified under the Canadian Hazardous Products Act Ingredient Disclosure List: 0.1%.845(502)

Sodium hydroxide:

TSCA Inventory Status: Listed Canada DSL: Listed

Sodium Chloride:

TSCA Inventory Status: Listed EINECS Number: 231-598-3

Canada DSL: Listed

Water for Injection:

TSCA Inventory Status: Listed Canada DSL: Listed

SECTION 16: ADDITIONAL INFORMATION

HMIS Ratings:

HMIS Health Hazard: 1 HMIS Fire Hazard: 1 HMIS Reactivity: 1 HMIS Personal Protection: Χ

SDS Creation Date: January 08, 2009 SDS Revision Date: June 10, 2015

SDS Format:

Disclaimer:

The information contained herein pertains to this material. It is the responsibility of each individual party to determine for themselves the proper means of handling and using these materials based on their purpose and intended use. Fresenius-Kabi assumes no liability resulting from the use of or reliance upon the information contained in this material safety data sheet. This material safety data sheet does not constitute the guaranty or specifications of the product.

Copyright© 1996-2015 Actio Corporation. All Rights Reserved.